Correlation Engine 2.0
Clear Search sequence regions


  • androgen (1)
  • antiandrogen (4)
  • cytokines (1)
  • humans (1)
  • patients (2)
  • prostate (3)
  • proteins gene (1)
  • receptor (1)
  • Sizes of these terms reflect their relevance to your search.

    Prostate cancer therapy for locally advanced and metastatic diseases includes androgen deprivation therapy (ADT). Second-generation antiandrogens have a role in castration-resistant prostate cancer. Nevertheless, some patients do not respond to this therapy, and eventually all the patients became resistant. This is due to modifications to intracellular signaling pathways, genomic alteration, cytokines production, metabolic switches, constitutional receptor activation, overexpression of some proteins, and regulation of gene expression. The aim of this review is to define the most important mechanisms that drive this resistance and the newest discoveries in this field, specifically for enzalutamide and abiraterone, with potential implications for future therapeutic targets. Furthermore, apalutamide and darolutamide share some resistance mechanisms with abiraterone and enzalutamide and could be useful in some resistance settings.

    Citation

    Francesco Pinto, Francesco Dibitetto, Mauro Ragonese, Pierfrancesco Bassi. Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. Medical sciences (Basel, Switzerland). 2022 Apr 28;10(2)

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35645241

    View Full Text